

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

1-11. (Cancelled)

12. (Currently amended) A substantially purified polypeptide comprising an amino acid sequence at least 90% identical to SEQ ID NO:4, provided said polypeptide comprises MMPKHCL/ELG L/ELL, (SEQ ID NO:13) and amino acids 67-98 of SEQ ID NO:4, and wherein said polypeptide binds IL-10 or IL-22.

13. (Previously presented) The polypeptide of claim 12, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:4.

14. (Previously presented) A fusion polypeptide comprising the polypeptide of claim 12 linked to a non-CRF2-12 polypeptide.

15. (Previously presented) The fusion polypeptide of claim 14, wherein said non-CRF2-12 polypeptide comprises at least one member selected from the group consisting of an Fc region of an immunoglobulin molecule, a FLAG epitope, a HIS tag, and a MYC tag.

16. (Original) A pharmaceutical composition comprising the polypeptide of claim 12 and a pharmaceutically acceptable carrier.

17. (Cancelled)

18. (Currently amended) A kit comprising in one or more containers the ~~CRF2-12~~ polypeptide of claim 12.

9-70. (Cancelled)

71. (Currently amended) The polypeptide of claim 12, wherein said polypeptide comprises at least one the polypeptide sequences sequence selected from the group consisting of MMPKHCL/FLG-L/FLI, (SEQ ID NO:13), FQSRNFHNILH/QWQ A/PG (SEQ ID NO:14), SI/VYFVQYKM/IYGQS/RQW (SEQ ID NO:15), TPRFTPWWETKL/IDPPV (SEQ ID NO:16), LV/LYRVFT/IINNSLEKEQKA/VYEG (SEQ ID NO:17), RAVEIEG/ALI/TPHSSYCVVAEM/IYQPM (SEQ ID NO:18), and DRRSP/QRSK/EERCVQ/EIP (SEQ ID NO:19).

72. (Cancelled)

73. (Previously presented) The polypeptide of claim 12, wherein the amino acid sequence of said polypeptide is at least 95% identical to SEQ ID NO:4.

74. (Previously presented) The polypeptide of claim 12, wherein the amino acid sequence of said polypeptide is at least 98% identical to SEQ ID NO:4.

75. (Previously presented) The polypeptide of claim 12, wherein the amino acid sequence of said polypeptide is at least 99% identical to SEQ ID NO:4.

76. (Previously presented) The polypeptide of claim 12, wherein said polypeptide binds IL-10.

77. (Previously presented) The polypeptide of claim 12, wherein said polypeptide binds IL-22.

78-91. (Cancelled)